Conexeu Sciences Is Coming After The Opportunity Created By GLP-1’s

Mentioned:

CNXU -1.32%

Conexeu Sciences is coming after a new opportunity: the knock on effects caused by GLP-1 weight loss drugs.

What’s happening:

Conexeu Sciences (NASDAQ: CNXU) has successfully completed their 12 month preclinical study focused on evaluating their proprietary CXU platform as a potential tissue restoration solution for medical aesthetics

Why it matters:‍

Conexeu Sciences’ study demonstrated that their CXU platform met its objectives for tissue restoration in a facial model and is designed to be delivered through a fine-gauge needle for precise placement with potential as an injectable aesthetic

Going deeper:‍

The completed study advances Conexeu Sciences’ CXU platform toward a potential role in supporting the tissue changes that can follow GLP-1 weight loss, including both facial volume loss and skin laxity
Conexeu Sciences’ preclinical study included both a small-volume facial model and a larger-volume body model to evaluate the performance of their CXU platform for tissue restoration in areas commonly affected by weight loss related volume loss
Conexeu Sciences also just recently made waves when they publicly stated they have begun scaling up its manufacturing and standardized formulation methods with their contract development and manufacturing organization for their lead wound care device candidate Ten Minute Tissue in order to support their planned 510(k) submission to the United States Food and Drug Administration

The intrigue:‍

Conexeu Sciences’ CXU platform was developed through more than a decade of university preclinical research and owns the issued patents in the United States, Japan, Australia and the European Union

‍

Disclaimer

The New Money provides background information on early stage companies from publicly available sources. The New Money provides no advice on dealing in securities, is not a financial adviser and does not pretend to be so. This message is meant for information and educational purposes only. The information contained in this article is not to be considered factual or complete. Anybody interested in obtaining financial and other information on companies mentioned is advised to get it direct from the companies, or from their own investment adviser. The New Money does not intend for this information to be used to inform an investment decision.

The New Money has been compensated by Conexeu Sciences for a media campaign, which affects our ability to be unbiased. The Principals of The New Money may buy or sell shares of the company without further notice. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities. The New Money and its principals and agents are not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Always do your own research and consult with a licensed investment professional before making an investment.

This communication should not be used as a basis for making any investment. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy or Sell securities. No representation is being made that any stock trade will or is likely to achieve profits. Comparisons made to other featured companies or past performance is not indicative of future results.